Gilead's Kite gains license to Refuge Biotechnologies platform for blood cancer treatments
Justin Sullivan


Gilead Sciences' (NASDAQ:GILD) Kite unit has signed a licensing agreement with Refuge Biotechnologies gaining access to the latter's gene expression platform to develop treatments for blood cancers.
The Refuge platform is a synthetic biology system that uses an expression modulation strategy to inhibit or activate transcription of target genes.

Terms call for Kite to have an exclusive license to Refuge's intellectual property portfolio for use in blood cancers, and also a library of synthetic gene expression programs for the indications. Refuge retains the rights and programs related to solid tumor indications.
See why Seeking Alpha contributor Oyat says that Gilead's (GILD) growth potential is underappreciated.